Crinetics Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Crinetics Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $185M, a 46.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $185M +$58.9M +46.8% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $126M +$40.5M +47.3% Dec 31, 2022 10-K 2024-02-28
Q4 2021 $85.5M +$34.6M +68% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $50.9M +$22.3M +77.9% Dec 31, 2020 10-K 2022-03-30
Q4 2019 $28.6M +$16M +127% Dec 31, 2019 10-K 2021-03-30
Q4 2018 $12.6M +$7.72M +159% Dec 31, 2018 10-K 2020-03-09
Q4 2017 $4.86M Dec 31, 2017 10-K 2019-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.